CD8A and neoplasm: For RT in HCC patients, we use therapeutic dose (3–5 Gy/fraction, a total dose of 40–50 Gy) to treat the targeted tumor lesion, which could release more tumor-associated antigens for immune system activation; secondly, in terms of the method and time of poly(I:C) injecting, subcutaneous injection of poly(I:C) was performed in every two days in the entire RT cycle, which could help to make full use of tumor-associated antigens released from RT treatment in real time to promote antigen presentation and CD8+ T cell activation.